Dr. Everts has built a distinguished career of over 35 years as a clinician, researcher, and executive, with specialized expertise in medical devices and biological therapies used in orthobiology-msk, spine, chronic wound care, cardiac surgery, reconstructive surgery, facial aesthetics, hair regrowth, and other regenerative medicine applications.
Prior to joining ZEO, Dr. Everts served as Chief Scientific Officer at EmCyte Corporation and Educational Program Director at Gulf Coast Biologics, where he led research and development efforts focused on autologous biological protocols to improve patient outcomes in musculoskeletal and spine disorders. In 2010, Dr. Everts co-founded the Da Vinci Clinic in the Netherlands, where he served as Chairman of the Board of Directors, specializing in hyperbaric medicine and advanced biological therapies for complex chronic wound care. He also held senior leadership roles at Avance Medical (Switzerland), directing regenerative medicine and cell therapies for European and Middle East markets. His international collaborations with universities and research centers have contributed to significant advancements in the field.
Dr. Everts earned his Ph.D. in Medicine from the University of Utrecht, the Netherlands, and currently holds an Adjunct Professorship at the University of Queensland, Brisbane (Australia) and an International Professorship at Max Planck University, Indaiatuba (Brazil).
Dr Everts commented, “the opportunity to join the ZEO team is both exciting and rewarding as ZEO is committed to advancements in innovative biological therapeutics for regenerative medicine, based on safety and evidence-based data.”
“We are excited to welcome Dr. Everts to the ZEO ScientifiX™ leadership team,” said Ian Bothwell, Interim CEO and CFO of ZEO. “His vast experience and leadership will be instrumental as we continue to develop innovative biologic therapeutic products and seek to advance our clinical trial portfolio.”
In addition, Mr. Bothwell added, “this strategic addition to ZEO’s executive team underscores the Company’s commitment to accelerating innovation, enhancing patient outcomes, and expanding the commercial potential of regenerative therapies. As investors seek to capitalize on the exponential growth of the biologic medicine industry, we believe that Dr. Everts’ leadership will play a pivotal role in guiding the Company’s scientific advancements and reinforcing its market position”.
